bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.92 USD
+0.01 (1.13%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.93 +0.01 (0.78%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
BLUE 0.92 +0.01(1.13%)
Will BLUE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BLUE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BLUE
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
BLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
Other News for BLUE
bluebird bio Announces Receipt of Expected Notice from Nasdaq
Market Today: Tech Giants Reignite AI Craze, Alibaba Continues Winning Streak
Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
bluebird bio receives non-compliance notice from Nasdaq
Bluebird Bio receives expected notice from Nasdaq